By Matt Grossman

 

Sanofi and Translate Bio Inc.'s candidate Covid-19 vaccine showed positive results in early trials using mice and non-human primates, the companies said Thursday.

In a pre-clinical trial, mice were given two doses of the candidate vaccine at one of four studied dose levels. The vaccine induced dose-dependent levels of binding and neutralizing antibodies, Sanofi and Translate said.

The vaccine was also studied in non-human primates, which were given the vaccine at one of three dose levels. The majority of the primates developed neutralizing antibodies after one dose, and antibody titers for all of the creatures reached levels significantly higher than those from human convalescent sera after a second dose.

The companies plan to begin a Phase 1/2 clinical trial of the vaccine by the end of the year.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

October 15, 2020 08:31 ET (12:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.